Experimental quantification of transmission of genetically engineered pseudorabies virus.
There is concern that live pseudorabies virus (PRV) vaccine or PRV vector vaccine strains may spread from vaccinated to unvaccinated pigs. Moreover, it is feared that recombining PRV vaccine strains with related vaccine or wild-type strains may lead to spread and survival of recombinant PRV. To learn more about to what extent different PRV vaccine strains could spread we used a previously described experimental model to study the transmission of intranasally inoculated PRV mutant strains under experimental conditions. We used PRV strains that lacked glycoprotein E (gE) or thymidine kinase (TK), and a PRV vector vaccine (gE-, TK-, gG-) that expresses the glycoprotein E1 (E1) of hog cholera virus. In addition, we investigated whether intranasally co-inoculated gE-negative and gE-positive PRV strains competed in transmission among pigs. The extent of transmission was estimated using the reproduction ratio R. This ratio has a threshold property; when R1, the infection can spread; when R < 1, the infection will disappear. We found that R for a gE-negative strain was 10.1, and R for a TK-negative strain was 5. Furthermore, the R for the vector vaccine (gE-, TK-, gG-) expressing E1 was 0.18, and did not differ significantly from the R for the control strain without E1. The R of gE-negative strain was significantly 1 (P = 0.0005). Co-inoculation with a gE-positive field strain did not prevent the transmission of a gE-negative strain. This study shows that a small-scale experiment can be used to estimate the transmission of genetically engineered organisms in their host species. The results of this study indicate that the deletion of gE alone or TK alone is not enough to prevent spread of PRV among susceptible pigs, and that transmission of gE-negative PRV is not firmly limited by co-presence of a gE-positive strain.
Mulder
W A
WA
Institute for Animal Science and Health, Department of Porcine and Exotic Viral Diseases, AJ Lelystad, The Netherlands.
De Jong
M C
MC
Priem
J
J
Bouma
A
A
Pol
J M
JM
Kimman
T G
TG
D000281:Administration, Intranasal; D000818:Animals; D005818:Genetic Engineering; D005822:Genetic Vectors; D011558:Herpesvirus 1, Suid / Q000235:genetics / Q000502:physiology*; D009154:Mutation; D011557:Pseudorabies / Q000635:transmission*; D013552:Swine; D014614:Vaccines, Synthetic
D014614:Vaccines, Synthetic